Vnitr Lek 2025, 71(3):185-189 | DOI: 10.36290/vnl.2025.032

Leishmaniasis as a rare case of bone marrow suppression

Aleš Tenk
Interní oddělení II, Nemocnice Most, o. z.

Bone marrow decline hides a plethora of etiopathogenetic causes, which the physician tries to understand. Our patient's case was all the more tricky because she was an immunocompromised person whose clinical picture and laboratory results were distorted by immunosuppressive therapy. In the following article, we try to highlight the importance of taking basic anamnestic data that should not be neglected and thorough physical and laboratory investigations. The highly erudite haematology department played a major, if not the most important role and is greatly helped with the diagnosis and subsequent treatment and is to be thanked. I believe that the following article will enrich every physician of different specialties with a very interesting and rare matter.

Keywords: leishmania, bone marrow, immunosuppression.

Accepted: April 28, 2025; Published: May 16, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tenk A. Leishmaniasis as a rare case of bone marrow suppression. Vnitr Lek. 2025;71(3):185-189. doi: 10.36290/vnl.2025.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baba CS, Makharia GK, Mathur P, et al. Chronic diarrhea and malabsorption caused by Leishmania donovani. Indian J Gastroenterol. 2006;25:309-310.
    2. Bogdan, Ch. Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example. Cell Microbiol. 2008;10(6):1221-1234. Available from: https://doi.org/10.1111/j.1462-5822.2008.01146.x. Go to original source... Go to PubMed...
    3. Bora K, Sarma M, Kanaujia SP, et al. Development of novel dual-target drugs against visceral leishmaniasis and combinational study with miltefosine. Free Radic Biol Med. 2024;225:275-285. Available from: https://doi.org/10.1016/j.freeradbiomed.2024. 10. 257. Go to original source...
    4. Brimo Alsaman MZ, Abu Sultan F, Ramadan Y, et al. Visceral leishmaniasis complicated with hemophagocytic lymphohistiocytosis and resistant to amphotericin B: a case report. J Med Case Reports. 2024;18(1):423. Available from: https://doi.org/10.1186/s13256-024-04760-4. Go to original source... Go to PubMed...
    5. Gelaw YM, Gangneux JP, Alene G, et al. Barriers and facilitators of visceral leishmaniasis case management in the Amhara Region, Northwest Ethiopia: an exploratory qualitative study. BMC Public Health. 2024;24: 2500. Available from: https://doi.org/10.1186/s12889-024-20055-1. Go to original source... Go to PubMed...
    6. Hamarsheh O, Guernaoui S, Karakus M, et al. Population structure analysis of Phlebotomus papatasi populations using transcriptome microsatellites: possible implications for leishmaniasis control and vaccine development. Parasit Vectors. 2024;17(1):410. Available from: https://doi.org/10.1186/s13071-024-06495-z. Go to original source... Go to PubMed...
    7. Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF (eds). Tropical infectious Diseases: Principles, Pathogens and Practice, 3rd ed. Philadelphia 2011: 696-706. ISBN 978-07-0203-935-5. Go to original source...
    8. Lodi L, Voarino M, Stocco S, et al. Immune response to viscerotropic Leishmania: a comprehensive review. Fron Immunol. 2024;15:1402539. Available from: https://doi.org/10.3389/fimmu.2024.1402539. Go to original source... Go to PubMed...
    9. Sarfraz A, Sarfraz Z, Liaqat M, et al. Leishmaniasis - Still a diagnostic challenge: An individual participant data systematic review. Trop Doct. 2024;54(4):352-358. Available from: https://doi:10.1177/00494755241273086. Go to original source... Go to PubMed...
    10. Sznayi J, Prášil J, Smetana J. Viscerální leishmanióza. Vakcinologie. 2019;13(1):27-30. Go to original source...
    11. Základní a aktuální informace. Data from June 2022. SZÚ. Leishmanióza. [cit. 2024-12-04]. Available from: https://szu.gov.cz/temata-zdravi-a-bezpecnosti/a-z-infekce/l/leishmanioza/leishmanioza-zakladni-a-aktualni-informace/.
    12. Tabbabi A, Mizushima D, Yamamoto DS, et al. Comparative analysis of the microbiota of sand fly vectors of Leishmania major and L. tropica in a mixed focus of cutaneous leishmaniasis in southeast Tunisia; ecotype shapes the bacterial community structure. PLOS Negl Trop Dis. 2024;18(9):e0012458. Available from: https://doi.org/10.1371/journal.pntd.0012458. Go to original source... Go to PubMed...
    13. Zdobinská Reisingerová H, Votýpka J. Leishmanióza a další infekce prvoky. In: Třešňáková Hergocová J (eds). Klinická dermatovenerologie. Mladá fronta: Praha 2019:1439-1447. ISBN 978-80-204.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.